What is Salvia BioElectronics?
Founded in 2017 and headquartered at the High Tech Campus Eindhoven in the Netherlands, Salvia BioElectronics operates at the intersection of medical technology and neuroscience. The company is dedicated to the development of innovative neuromodulation therapies, a field that utilizes electrical stimulation to modulate the nervous system's activity. By focusing on chronic migraine and cluster headache, Salvia addresses a significant unmet medical need, targeting patient populations that have historically lacked effective, non-pharmacological treatment options. The company's strategic positioning within the European life sciences ecosystem, combined with its international clinical footprint, establishes it as a high-potential player in the global medical device market.
How much funding has Salvia BioElectronics raised?
Salvia BioElectronics has raised a total of $60M across 1 funding round:
Series B
$60M
Series B (2025): $60M with participation from EIC IMPACT TRUST - EIC IMPACT FUND - Eastern Investment Centers, Dolby Family Ventures, Inkef, Thuja Capital, Shs Capital, Panakes Partners, Invest-NL, and Innovative Industrial Properties
Key Investors in Salvia BioElectronics
Dolby Family Ventures
An investment firm focused on early-stage companies addressing significant science and engineering challenges, with a strong emphasis on precision neuroscience and life sciences platforms.
Thuja Capital
A leading early-stage venture capital firm specializing in innovative life science companies across Europe, dedicated to empowering breakthrough healthcare innovations.
Panakes Partners
A venture capital investor that finances medical companies and early-stage startups in Europe and Israel, focusing on medical devices, diagnostics, and healthcare IT.
What's next for Salvia BioElectronics?
With the successful closure of this major enterprise-level funding, Salvia BioElectronics is poised to scale its operational capabilities and deepen its clinical research initiatives. The strategic roadmap likely involves the expansion of multi-center clinical trials to solidify the efficacy and safety profiles of its neuromodulation platforms. Furthermore, the company is expected to utilize this capital to strengthen its intellectual property portfolio and refine its manufacturing processes to meet anticipated regulatory requirements in the United States and beyond. As the firm moves forward, the focus will remain on achieving clinical milestones that demonstrate superior patient outcomes, thereby enhancing its value proposition for future commercialization and potential strategic partnerships within the broader healthcare technology sector.
See full Salvia BioElectronics company page
